Publications

CRISPR 2.0 and CAR-T Cell Engineering

  1. Petri, K.†, D’Ippolito, E., Künkele, A., Köhl, U., Busch, D. H., Einsele, H. & Hudecek, M. † (2025). Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities. Nat Rev Clin Oncol, doi:10.1038/s41571-025-01072-4.
    †Corresponding author

  2. Petri, K.*, Zhang, W.*, Ma, J.*, Schmidts, A.*, Lee, H., Horng, J. E., Kim, D. Y., Kurt, I. C., Clement, K., Hsu, J. Y., Pinello, L., Maus, M. v, Joung, J. K., & Yeh, J.-R. J. (2022). CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells.
    Nature Biotechnology, 40(2), 189–193. https://doi.org/10.1038/s41587-021-00901-y
     
  3. Petri, K., & Grünewald, J. (2023). An update on prime editing: recent advances and applications.
    Cell and Gene Therapy Insights, 9(9), 1359–1365. https://doi.org/10.18609/cgti.2023.174
     
  4. Zhang, W., Petri, K., Ma, J., Lee, H., Tsai, C.-L., Joung, J. K., & Yeh, J.-R. J. (2023). Enhancing CRISPR prime editing by reducing misfolded pegRNA interactions.
    eLife, 12. https://doi.org/10.7554/ELIFE.90948
     
  5. Grünewald, J., Miller, B. R., Szalay, R. N., Cabeceiras, P. K., Woodilla, C. J., Holtz, E. J. B., Petri, K., & Joung, J. K. (2022). Engineered CRISPR prime editors with compact, untethered reverse transcriptases.
    Nature Biotechnology 2022, 1–7. https://doi.org/10.1038/s41587-022-01473-1
     
  6. Annas, G. J., Beisel, C. L., Clement, K., Crisanti, A., Francis, S., Galardini, M., Galizi, R., Grünewald, J., Immobile, G., Khalil, A. S., Müller, R., Pattanayak, V., Petri, K., Paul, L., Pinello, L., Simoni, A., Taxiarchi, C., & Joung, J. K. (2021). A Code of Ethics for Gene Drive Research.
    The CRISPR Journal, 4(1), 19–24. https://doi.org/10.1089/crispr.2020.0096
     
  7. Hsu, J. Y., Grünewald, J., Szalay, R., Shih, J., Anzalone, A. v., Lam, K. C., Shen, M. W., Petri, K., Liu, D. R., Keith Joung, J., & Pinello, L. (2021). PrimeDesign software for rapid and simplified design of prime editing guide RNAs.
    Nature Communications 2021 12:1, 12(1), 1–6. https://doi.org/10.1038/s41467-021-21337-7
     
  8. Petri, K., & Pattanayak, V. (2018). SHERLOCK and DETECTR Open a New Frontier in Molecular Diagnostics.
    The CRISPR Journal, 1(3), 209–211. https://doi.org/10.1089/crispr.2018.29018.kpe

Assessing the Precision of CRISPR Gene Editing

  1. Zeng, J., Nguyen, M. A., Liu, P., da Silva, L. F., Levesque, S., Lin, L. Y., Justus, D. G., Petri, K., Clement, K., Porter, S. N., Verma, A., Neri, N. R., Rosanwo, T., Ciuculescu, M.-F., Abriss, D., Mintzer, E., Maitland, S. A., Demirci, S., Cha, H. J., … Bauer, D. E. (2024). Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells.
    Cell Stem Cell. https://doi.org/10.1016/j.stem.2024.11.001
     
  2. Petri, K., Kim, D. Y., Sasaki, K. E., Canver, M. C., Wang, X., Shah, H., Lee, H., Horng, J. E., Clement, K., Iyer, S., Garcia, S. P., Guo, J. A., Newby, G. A., Pinello, L., Liu, D. R., Aryee, M. J., Musunuru, K., Joung, J. K., & Pattanayak, V. (2021). Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects.
    bioRxiv, 2021.04.05.438458. https://doi.org/10.1101/2021.04.05.438458
     
  3. Garrood, W. T., Kranjc, N., Petri, K., Kim, D. Y., Guo, J. A., Hammond, A. M., Morianou, I., Pattanayak, V., Joung, J. K., Crisanti, A., & Simoni, A. (2021). Analysis of off-target effects in CRISPR-based gene drives in the human malaria mosquito.
    Proceedings of the National Academy of Sciences of the United States of America, 118(22). https://doi.org/10.1073/PNAS.200483811
     
  4. Konstantinidis, E., Molisak, A., Perrin, F., Streubel-Gallasch, L., Fayad, S., Kim, D. Y., Petri, K., Aryee, M. J., Aguilar, X., György, B., Giedraitis, V., Joung, J. K., Pattanayak, V., Essand, M., Erlandsson, A., Berezovska, O., & Ingelsson, M. (2022). CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer's disease PSEN 1 M146L mutation.
    Molecular Therapy. Nucleic Acids, 28, 450–461. https://doi.org/10.1016/J.OMTN.2022.03.022
     
  5. Knipping, F., Osborn, M. J., Petri, K., Tolar, J., Glimm, H., von Kalle, C., Schmidt, M., & Gabriel, R. (2017). Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor Modification.
    Molecular Therapy - Methods and Clinical Development, 4. https://doi.org/10.1016/j.omtm.2017.01.005

Integration Site Profiling of Viruses and Viral Vectors

  1. Petri, K.*, Gabriel, R.*, Agundez, L.*, Fronza, R., Afzal, S., Kaeppel, C., Linden, R. M., Henckaerts, E., & Schmidt, M. (2015). Presence of a trs-like motif promotes Rep-mediated wildtype adeno-associated virus type 2 integration.
    Journal of Virology, 89(14). https://doi.org/10.1128/JVI.00426-15  
     
  2. Petri, K., Fronza, R., Gabriel, R., Käppel, C., Nowrouzi, A., Linden, R. M., Henckaerts, E., & Schmidt, M. (2014). Comparative next-generation sequencing of adeno-associated virus inverted terminal repeats.
    BioTechniques, 56(5), 269–273. https://doi.org/10.2144/000114170 

Contact

Dr. med. Karl Petri | Group leader | +49 931 201-44817 | petri_k@ukw.de

Address

Medical Clinic and Policlinic II | Versbacher Straße 5 | 97078 Wuerzburg | Germany